Search the Internet          Tips  Sites: Finance, Investment

Pfizer to foray into 2 veterinary lines

Rajesh Unnikrishnan

The animal health division of the Pfizer India is planning a foray into two new segments -- animal vaccine and nutritional products.

The company in its latest annual report said, "Pfizer's animal health division has plans to make a foray into the companion animal business during the year through companion animal vaccines and nutritional products." At the same time, the report said, the animal health division will continue to focus on the poultry and large animal segments.

Growth for the year 2000 has been propelled by the poultry business, driven primarily by feed supplements.

The animal health market is estimated to be around Rs 8 billion in the country with the poultry sector contributing 45 per cent, the cattle and sheep around 50 per cent and the companion animal business around 5 per cent.

Two major veterinary brands -- Coxistac and Stafac -- have continued to have commanding position in their respective segments. The launch of Megamycine in the cattle business has further strengthened Pfizer's position in the anti-infective segment, the report said.

It added that the upgradation of the New Bombay plant is in progress and is expected to be completed in the next 18 months. Subsequent to this upgradation, the plant facilities will be benchmarked to the best manufacturing standards. Similarly, the report said, the Chandigarh plant has been used to full capacity with the bulk drug chloroprop amid being exported to the international Pfizer locations.

Powered by

ALSO READ:
The Rediff-Business Standard Special
The Budget 2001-2002 Special
Money
Business News

Tell us what you think of this report